CVRx, Inc.CVRX

CVRx Inc. sells a neuromodulation device called Barostim™, billing it on its own website as the world’s first heart failure treatment of its kind-a medical claim that looks heroic until you open the 10-Q from March 31, 2026 and find revenue of just $14.8 million and a net loss of $13.1 million. The company’s own product pages promise life-changing therapy, but the balance sheet is stuck in a life-support mode, with liabilities of $70.6 million, equity of $29.1 million, and cash burn so deep it makes the CFO transition announcement feel like a sideshow rather than a rescue. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1235912/000165818025000003/0001658180-25-000010-index.htm)

Barostim’s marketing site offers patient stories, a questionnaire to check eligibility, and images of smiling implant recipients, all framed as a breakthrough in heart failure management. Behind the gloss, CVRx is a medical device outfit with a single flagship product, a burn rate that gobbles cash faster than a hospital cafeteria on visiting day, and no segment diversification to cushion the blow. The device may be novel, but the operating model is classic early-stage: negative operating income of $12.2 million in Q1 2026, R&D of $3.1 million, and capex so small ($122,000) it barely registers against the cash drain. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1235912/000165818025000003/0001658180-25-000010-index.htm)

Filing by filing, the picture is consistent: revenue of $14.8 million, net loss of $13.1 million, diluted EPS of -$0.50, and 26.4 million diluted shares outstanding. Cash and equivalents stand at $72.3 million, but operating cash flow is -$12.2 million, and inventory has crept up by $198,000 to $12.4 million-a stockpile of goods that sits awkwardly against a shrinking runway. The company’s June 9, 2026 8-K announcing a CFO transition arrived with the thud of a press release that read like a LinkedIn post, followed the same day by three Form 4 filings from insiders selling shares they hadn’t yet vested. (source: 8-K dated 2026-06-09, https://www.sec.gov/Archives/edgar/data/1235912/000110465926071595/tm2617208d1_8k.htm)

The company’s own rails-home page, patient stories, eligibility questionnaire-paint Barostim as a therapy option for the right patient, but the SEC filings paint a company that is still burning through cash faster than it can convince the market it has a sustainable path to profitability. The device may be cutting-edge; the capital structure is not. The company’s story is built on neuromodulation, but its filings are built on negative operating cash flow and a shrinking equity base. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1235912/000165818025000003/0001658180-25-000010-index.htm)

What’s missing from the evidence is a clear path to cash-flow positivity, segment diversification, or a credible buyback programme to offset dilution. The company’s R&D spend is steady at $3.1 million, but there’s no sign of a near-term catalyst large enough to flip the operating-income dial from red to black. Until revenue growth accelerates above burn, or the company secures non-dilutive financing, Barostim’s promise will stay on the website and the losses will stay on the income statement. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1235912/000165818025000003/0001658180-25-000010-index.htm) For chart context, the company trades on OTC Markets under the symbol CVRX.OB with thin liquidity; no exchange depth or level data is supplied in the filings, so any attempt to infer support or resistance would be speculation rather than evidence. (source: SEC EDGAR company facts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001235911.json)